In this paper, we tested whether engineered exosomes could achieve targeted delivery of miR-25 and miR-181a to the brain of SCA3 mice and whether miR-25 and miR-181a could alleviate neuropathology by reducing the ATXN3 level in vivo. The gene discussed is ATXN3; the disease is Machado-Joseph disease.